About Us
Products
Responsibility
Investors
Media
Careers
Worldwide
- North America
  - USA
  - Canada
  - Mexico
- South America
  - Brazil
  - Peru
- Asia Pacific
  - India
  - Bangladesh
  - Thailand
  - Malaysia
  - Singapore
  - Myanmar
  - Sri Lanka
  - Japan
  - China
- Europe
  - Denmark
  - Finland
  - France
  - Germany
  - Hungary
  - Italy
  - Norway
  - Poland
  - Romania
  - Spain
  - Sweden
  - Switzerland
  - The Netherlands
  - The United Kingdom & Ireland
- Middle East
  - UAE
- Africa
  - Morocco
  - Nigeria
  - South Africa
  - Egypt
  - Kenya
- Oceania
  - Australia & New Zealand
- CIS
  - Russia
  - Ukraine
Contact Us

Select Page

SPIL Q1FY27 Financial Results

by ananthi | Jul 31, 2026 | Press Releases | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Search for:

Recent Posts

Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments
SPIL Q1FY27 Financial Results
Sun Pharma reports Q1FY27 results
Sun Pharma receives approval to manufacture and market semaglutide in Brazil
Sun Pharma launches generic semaglutide in South Africa

Recent Comments

About Sun Pharma
- Vision & Values
- Milestones & Recognitions
Operations
Investors
Work with us
- Careers
- Current Openings
Quick Links

Facebook
X
Instagram
Linkdin
Instagram

Copyright © Sun Pharmaceutical Industries Ltd. Privacy Policy | Disclaimer

Top

Important Notice

As per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 it is mandatory for all the shareholders holding shares in physical form to update their KYC and other details.